Zymeworks Inc.
NASDAQ · ZYME·Vancouver, Canada·Mid-cap·Approved
Develops multifunctional biotherapeutics for difficult-to-treat cancers. Partnered asset Ziihera (zanidatamab) is approved for HER2+ biliary tract cancer with Phase 3 data in gastroesophageal adenocarcinoma. Proprietary pipeline is led by ZW191, an FRa-targeting ADC with FDA Fast Track and 61% ORR in platinum-resistant ovarian cancer.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Zymeworks Corporate Deck March 2026 | Corporate overview | March 1, 2026 | 28 |